ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Baron & Budd Announces Fall 2024 Mesothelioma Cancer Victims Memorial Scholarship Winners

Scholarship winners Devan Tatlow and Braden Fleagle share their personal battles with cancer.

Today, the national law firm of Baron & Budd announced that it has selected Devan Tatlow and Braden Fleagle as the winners of the Mesothelioma Cancer Victims Memorial Scholarship. Each winner will receive a $2,500 scholarship paid directly to the financial aid accounts at their universities.

Applicants were asked to submit a written or video essay about how cancer has impacted their lives. Devan Tatlow’s winning written essay was selected after a competitive review by the Baron & Budd Scholarship committee. His remarkably impressive essay detailed his battle with Acute Promyelocytic Leukemia and how his experience with the disease helped him to see the deficiencies in healthcare in high-poverty countries. Tatlow decided to take what he learned from his illness and become an advocate for childhood cancer patients by addressing the Congressional Childhood Cancer Caucus on multiple occasions, raising millions of dollars for cancer foundations, and fighting for children and their families in war-torn Ukraine to help them get access to cancer treatments.

In his essay Tatlow wrote, “Over three decades, my form of leukemia has gone from a death sentence to curable—in wealthy countries, that is. Where I was born in Colombia, fewer than 1 in 5 children survive cancer; here, more than 4 in 5 do. Even in America, kids in high-poverty counties are 18% more likely to die of cancer than kids in wealthier ones, according to the American Cancer Society. These kids don’t just die of cancer; they die of our failure to provide equitable health care.” He goes on to say, “Surviving cancer has made me grateful for life’s highs—and its lows. I never take waking up for granted and I’m attuned to people’s struggles. It’s also made me passionate about health equity. I am a freshman at Harvard, and I hope to study the genetic, socio-economic, and environmental determinants of disease; research treatments; and learn to use policy and the law to help others get access to life-saving medical care.”

Tatlow is currently attending Harvard University and participates on the debate team and the satellite team where they are building a satellite to launch into space.

Additionally, Braden Fleagle was selected as the video essay winner. His video focused on his own struggles with germinoma brain cancer and how it affected him and his family. Fleagle described the challenges he has faced during his cancer journey and explained how it influenced his plans for the future.

Fleagle said he planned “to go to a big college, take five or six classes a semester, have a part time job, be in marching band and then hopefully work as a CFO for a Fortune 500 company in a corner office.” He went on in his video to explain how his goals have since changed to, “getting a degree to work for Four Diamonds, St. Jude’s, or another non-profit organization with a similar mission, finding a cure for this terrible disease. Cancer changed me and my future in what I am planning to do with my life and what I want to work towards.”

Fleagle is attending Penn State World Campus where he is pursuing a degree in health policy and administration. He is also a member of the World Campus Student Government Association and the American College Healthcare Administrators.

In one of his letters of recommendation, his college advisor said, “Braden has demonstrated a deep commitment to raising awareness about pediatric cancer and the impact it has on individuals and families. His involvement in THON™ showcases not only his dedication but also his ability to inspire others to take action. He possesses a unique combination of empathy and leadership skills that make him an ideal candidate for this scholarship as a pediatric cancer survivor.”

“Devan and Braden are inspirational and compassionate individuals, finding purpose through their illness and dedicating much of their lives to helping others. We wish them continued success in all their future endeavors and are proud to help support their education,” said President and Managing Shareholder Russell Budd.

The Mesothelioma Cancer Victims Memorial Scholarship was established to honor the legacy of the thousands of Americans who are diagnosed with mesothelioma cancer every year. For more information about the Baron & Budd Mesothelioma Cancer Victims Memorial Scholarship, please visit baronandbudd.com/mesothelioma-lawyer/scholarships/.

About Baron & Budd, P.C.

With more than 40 years of experience, Baron & Budd has the expertise and resources to handle complex litigation throughout the United States. As a law firm that takes pride in remaining at the forefront of litigation, Baron & Budd has spearheaded many significant cases for hundreds of public entities and tens of thousands of individuals. Since the firm was founded in 1977, Baron & Budd has achieved substantial national acclaim for its work on cutting-edge litigation, trying hundreds of cases to verdict and settling tens of thousands of cases in areas of litigation as diverse and significant as dangerous and highly addictive pharmaceuticals, defective medical devices, asbestos and mesothelioma, wildfires, environmental contamination, fraudulent banking practices, e-cigarettes, motor vehicles, federal whistleblower cases, and other consumer fraud issues.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.